Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Department of Genetics, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 10/2001; 98(19):10869-74. DOI: 10.1073/pnas.191367098
Source: PubMed

ABSTRACT The purpose of this study was to classify breast carcinomas based on variations in gene expression patterns derived from cDNA microarrays and to correlate tumor characteristics to clinical outcome. A total of 85 cDNA microarray experiments representing 78 cancers, three fibroadenomas, and four normal breast tissues were analyzed by hierarchical clustering. As reported previously, the cancers could be classified into a basal epithelial-like group, an ERBB2-overexpressing group and a normal breast-like group based on variations in gene expression. A novel finding was that the previously characterized luminal epithelial/estrogen receptor-positive group could be divided into at least two subgroups, each with a distinctive expression profile. These subtypes proved to be reasonably robust by clustering using two different gene sets: first, a set of 456 cDNA clones previously selected to reflect intrinsic properties of the tumors and, second, a gene set that highly correlated with patient outcome. Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor budding refers to single or small cluster of tumor cells detached from the main tumor mass. In colon cancer high tumor budding is associated with positive lymph nodes and worse prognosis. Therefore, we investigated the value of tumor budding as a predictive feature of lymph node status in breast cancer (BC). Whole tissue sections from 148 surgical resection specimens (SRS) and 99 matched preoperative core biopsies (CB) with invasive BC of no special type were analyzed on one slide stained with pan-cytokeratin. In SRS, the total number of intratumoral (ITB) and peripheral tumor buds (PTB) in ten high-power fields (HPF) were counted. A bud was defined as a single tumor cell or a cluster of up to five tumor cells. High tumor budding equated to scores averaging >4 tumor buds across 10HPFs. In CB high tumor budding was defined as ≥10 buds/HPF. The results were correlated with pathological parameters. In SRS high PTB stratified BC with lymph node metastases (p ≤ 0.03) and lymphatic invasion (p ≤ 0.015). In CB high tumor budding was significantly (p = 0.0063) associated with venous invasion. Pathologists are able, based on morphology, to categorize BC into a high and low risk groups based in part on lymph node status. This risk assessment can be easily performed during routine diagnostics and it is time and cost effective. These results suggest that high PTB is associated with loco-regional metastasis, highlighting the possibility that this tumor feature may help in therapeutic decision-making.
    Breast Cancer Research and Treatment 03/2015; DOI:10.1007/s10549-015-3333-3 · 4.20 Impact Factor
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human epidermal growth factor receptor type 2 (HER2)-positive breast carcinoma is highly aggressive and mostly metastatic in nature though curable/manageable in part by molecular targeted therapy. Recent evidence suggests a subtype of cells within HER2-positive breast tumors that concomitantly expresses the urokinase plasminogen activator receptor (uPAR) with inherent stem cell/mesenchymal-like properties promoting tumor cell motility and a metastatic phenotype. This HER-positive/ uPAR-positive subtype may be partially responsible for the failure of HER2-targeted treatment strategies. Herein we discuss and substantiate the cumulative preclinical and clinical evidence on HER2-uPAR cooperativity in terms of gene co-amplification and/or mRNA/protein co-overexpression. We then propose a regulatory signaling model that we hypothesize to maintain upregulation and cooperativity between HER2 and uPAR in aggressive breast cancer. An improved understanding of the HER2/uPAR interaction in breast cancer will provide critical biomolecular information that may help better predict disease course and response to therapy. INTRODUCTION Breast cancer (BC) is a highly heterogeneous disease consisting of several subtypes, each classified by their unique biological signature [1, 2]. Each BC subtype exhibits varied responses to different therapeutic regimens. Treatment options for metastatic disease remains limited despite the availability of several United States Food and Drug Administration (FDA) approved drugs against BC [3]. In this scenario, it is imperative to explore different therapeutic models of targeting one or more tumor-specific biomarkers that define the more aggressive breast carcinoma subtypes efficiently for improved management of the disease. Established BC biomarkers predicting metastatic risk include lymph-node involvement, hormone independency, loss of histopathological differentiation of primary tumor (grade), elevated proliferation, and angiogenesis. However, these biomarkers confidently predict outcome for only ~30% of patients. Of the remaining patients some will still develop metastases whilst others will not [4]. Components of the urokinase plasminogen activation system, particularly urokinase plasminogen activator (uPA, Gene symbol: PLAU; located on chromosome 10q22.2), its receptor uPAR (Gene symbol: PLAUR; located on chromosome 19q13) and inhibitor plasminogen activator inhibitor type 1 (PAI-1, Gene symbol: SERPINE1; located on chromosome


Available from
Jun 3, 2014